KR102336767B1 - 골수증식성 신생물 및 만성 골수성 백혈병을 포함하는, 트랜스듀신 β―유사 단백질 １（ＴＢＬ １） 활성과 관련된 질환 또는 장애의 치료 방법 - Google Patents

골수증식성 신생물 및 만성 골수성 백혈병을 포함하는, 트랜스듀신 β―유사 단백질 １（ＴＢＬ １） 활성과 관련된 질환 또는 장애의 치료 방법 Download PDF

Info

Publication number
KR102336767B1
KR102336767B1 KR1020147015141A KR20147015141A KR102336767B1 KR 102336767 B1 KR102336767 B1 KR 102336767B1 KR 1020147015141 A KR1020147015141 A KR 1020147015141A KR 20147015141 A KR20147015141 A KR 20147015141A KR 102336767 B1 KR102336767 B1 KR 102336767B1
Authority
KR
South Korea
Prior art keywords
compound
cells
catenin
treatment
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147015141A
Other languages
English (en)
Korean (ko)
Other versions
KR102336767B9 (ko
KR20140089418A (ko
Inventor
카필 엔. 발라
스티븐 호리건
Original Assignee
베타 캐트 파마슈티칼스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베타 캐트 파마슈티칼스, 인코포레이티드 filed Critical 베타 캐트 파마슈티칼스, 인코포레이티드
Publication of KR20140089418A publication Critical patent/KR20140089418A/ko
Application granted granted Critical
Publication of KR102336767B1 publication Critical patent/KR102336767B1/ko
Publication of KR102336767B9 publication Critical patent/KR102336767B9/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020147015141A 2011-11-06 2012-11-06 골수증식성 신생물 및 만성 골수성 백혈병을 포함하는, 트랜스듀신 β―유사 단백질 １（ＴＢＬ １） 활성과 관련된 질환 또는 장애의 치료 방법 Active KR102336767B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161556245P 2011-11-06 2011-11-06
US61/556,245 2011-11-06
PCT/US2012/063746 WO2013067547A1 (en) 2011-11-06 2012-11-06 METHODS FOR TREATMENT OF DISEASES AND DISORDERS RELATED TO TRANSDUCIN β-LIKE PROTEIN 1 (TBL 1) ACTIVITY, INCLUDING MYELOPROLIFERATIVE NEOPLASIA AND CHRONIC MYELOID LEUKEMIA

Publications (3)

Publication Number Publication Date
KR20140089418A KR20140089418A (ko) 2014-07-14
KR102336767B1 true KR102336767B1 (ko) 2021-12-10
KR102336767B9 KR102336767B9 (ko) 2025-01-08

Family

ID=48192926

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147015141A Active KR102336767B1 (ko) 2011-11-06 2012-11-06 골수증식성 신생물 및 만성 골수성 백혈병을 포함하는, 트랜스듀신 β―유사 단백질 １（ＴＢＬ １） 활성과 관련된 질환 또는 장애의 치료 방법

Country Status (15)

Country Link
US (1) US9238030B2 (OSRAM)
EP (1) EP2773607B1 (OSRAM)
JP (1) JP6063472B2 (OSRAM)
KR (1) KR102336767B1 (OSRAM)
CN (1) CN103917514B (OSRAM)
AU (1) AU2012332111B2 (OSRAM)
BR (1) BR112014010584A2 (OSRAM)
CA (1) CA2853491C (OSRAM)
EA (1) EA027770B1 (OSRAM)
ES (1) ES2624427T3 (OSRAM)
IL (1) IL232452A (OSRAM)
MX (1) MX354653B (OSRAM)
SG (1) SG11201402056XA (OSRAM)
WO (1) WO2013067547A1 (OSRAM)
ZA (1) ZA201403003B (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9963475B2 (en) * 2015-07-28 2018-05-08 Beta Cat Pharmaceuticals, Inc. Anthracene-9, 10-dione dioxime compound prodrugs and their uses
JP2018523705A (ja) * 2015-07-28 2018-08-23 ベータ・キャット・ファーマシューティカルズ・インコーポレイテッド アントラセン−９，１０−ジオンジオキシム化合物プロドラッグ及びその使用
WO2018223023A1 (en) 2017-06-02 2018-12-06 Beta Cat Pharmaceuticals, Inc. Methods for treatment of fibrotic diseases
WO2019099836A1 (en) * 2017-11-16 2019-05-23 Northwestern University Inhaled formulation of a molecular inhibitor of wnt/beta-catenin signaling for treating interstitial lung diseases
WO2019229001A1 (en) * 2018-05-30 2019-12-05 Otto-Von-Guericke-Universität Magdeburg Compounds for the treatment of jak2-v617f-associated cmn
CN119215047A (zh) * 2024-10-11 2024-12-31 浙江大学 一种芳香磺酰胺类化合物在制备防治肝损伤药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010059142A1 (en) * 2008-11-21 2010-05-27 Avalon Pharmaceuticals Anthraquinone dioximes and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2584188T3 (es) * 2007-05-10 2016-09-26 Avalon Pharmaceuticals Derivados de fluoreno, antraceno, xanteno, dibenzosuberona y acridina y usos de los mismos
WO2008147713A1 (en) * 2007-05-24 2008-12-04 The Regents Of The University Of California Wnt signaling inhibitors, and methods for making and using them
CA2770320A1 (en) 2009-08-10 2011-02-17 Epitherix, Llc Indazoles as wnt/b-catenin signaling pathway inhibitors and therapeutic uses thereof
US20120157500A1 (en) 2009-08-24 2012-06-21 Weikang Tao Jak inhibition blocks rna interference associated toxicities
US20120244116A1 (en) 2009-10-01 2012-09-27 Csl Limited Method of treatment of philadelphia chromosome positive leukaemia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010059142A1 (en) * 2008-11-21 2010-05-27 Avalon Pharmaceuticals Anthraquinone dioximes and uses thereof

Also Published As

Publication number Publication date
MX2014005498A (es) 2016-05-05
US20130143920A1 (en) 2013-06-06
CN103917514B (zh) 2016-11-16
CA2853491C (en) 2019-12-10
EP2773607A1 (en) 2014-09-10
EP2773607B1 (en) 2017-03-29
NZ624446A (en) 2016-01-29
ES2624427T3 (es) 2017-07-14
IL232452A0 (en) 2014-06-30
AU2012332111A1 (en) 2014-05-22
EA201490937A1 (ru) 2014-08-29
HK1198440A1 (en) 2015-04-24
KR102336767B9 (ko) 2025-01-08
WO2013067547A1 (en) 2013-05-10
BR112014010584A2 (pt) 2017-05-02
US9238030B2 (en) 2016-01-19
MX354653B (es) 2018-03-07
SG11201402056XA (en) 2014-10-30
CA2853491A1 (en) 2013-05-10
JP6063472B2 (ja) 2017-01-18
IL232452A (en) 2017-01-31
CN103917514A (zh) 2014-07-09
EA027770B1 (ru) 2017-08-31
ZA201403003B (en) 2017-08-30
JP2014534229A (ja) 2014-12-18
KR20140089418A (ko) 2014-07-14
EP2773607A4 (en) 2015-03-11
AU2012332111B2 (en) 2016-11-17

Similar Documents

Publication Publication Date Title
KR102336767B1 (ko) 골수증식성 신생물 및 만성 골수성 백혈병을 포함하는, 트랜스듀신 β―유사 단백질 １（ＴＢＬ １） 활성과 관련된 질환 또는 장애의 치료 방법
AU2011302344B2 (en) HSP90 inhibitors for treating non-small cell lung cancers in wild-type EGFR and/or KRAS patients
US10583129B2 (en) Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer
ES2896735T3 (es) Eflornitina para su uso en el tratamiento del astrocitoma anaplásico recurrente/refractario por temozolomida
HK1251162A1 (en) Use of ep4 receptor antagonists for the treatment of nash-associated liver cancer
KR20080004495A (ko) 암을 치료하기 위한 조합물, 방법 및 조성물
EP3922251B1 (en) Cancer immunotheraphy adjuvant
EP3125901B1 (en) Derivatives of cephalosporin for treating cancer
CA3119036A1 (en) Anti-cancer activity of adamantane derivatives
US20190365680A1 (en) Use of ep4 receptor antagonists for the treatment of nash-associated liver cancer
HK1198440B (en) Treatment of diseases and disorders related to transducin beta-like protein 1 (tbl 1) activity, including myeloproliferative neoplasia and chronic myeloid leukemia
NZ624446B2 (en) Methods for treatment of diseases and disorders related to transducin ?-like protein 1 (tbl 1) activity, including myeloproliferative neoplasia and chronic myeloid leukemia
JP2025528834A (ja) 癌治療のための２－ｓリマンタジンおよび２－ｒリマンタジンの塩
EA044198B1 (ru) Комбинированная терапия для лечения рака предстательной железы
HK1233924B (en) Derivatives of cephalosporin for treating cancer
HK1233924A1 (en) Derivatives of cephalosporin for treating cancer

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

J201 Request for trial against refusal decision
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A17-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

J301 Trial decision

Free format text: TRIAL NUMBER: 2020101001304; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20200511

Effective date: 20210902

PJ1301 Trial decision

St.27 status event code: A-3-3-V10-V15-crt-PJ1301

Decision date: 20210902

Appeal event data comment text: Appeal Kind Category : Appeal against decision to decline refusal, Appeal Ground Text : 2014 7015141

Appeal request date: 20200511

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2020101001304

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PG1701 Publication of correction

St.27 status event code: A-5-5-P10-P19-oth-PG1701

Patent document republication publication date: 20250108

Republication note text: Request for Correction Notice (Document Request)

Gazette number: 1023367670000

Gazette reference publication date: 20211210

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 5